Regeneron Pharmaceuticals Inc banner

Intrinsic Value

The intrinsic value of Regeneron Pharmaceuticals Inc (0R2M) under the Base Case is USD per share. Compared with the current market price of 924.8081 USD, the stock appears .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

0R2M Intrinsic Value

What one share is worth in the bear, base and bull cases.

Create a free account · No card needed

Do our valuations actually work? See backtest results .

Alert me when 0R2M is below its intrinsic value
Today Hidden ·
0R2M Valuation History

Intrinsic value next to the price over the past 12 months.

Create a free account · No card needed

Alternatives to 0R2M

Fundamental Analysis

What Regeneron Pharmaceuticals Does

Biotechnology Health Care

Regeneron Pharmaceuticals makes prescription medicines, mostly biologic drugs that are built from antibodies and other protein-based therapies. It develops treatments for eye diseases, allergies, inflammation, cancer, and rare genetic disorders, then sells them through hospitals, clinics, pharmacies, and specialty distributors. Its main customers are patients and the doctors and health systems that treat them, along with insurers and government health programs that pay for the drugs.

Headquarters
United States of America US
Employees
15 410
IPO date
Apr 2, 1991
Read the full company overview
View Company Overview

Regeneron Pharmaceuticals has a narrow economic moat

No Moat Narrow Wide

Legal protection for medicines such as Dupixent and EYLEA HD prevents rivals from freely copying them, helping Regeneron preserve sales and profits. This protection covers specific medicines rather than whole treatment markets, where competing drugs remain available.

Read the full moat analysis
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · October 30, 2026

Record-setting brands and a broad pipeline define the quarter, while an expanded Sanofi alliance advances long-acting type 2 inflammation medicines.

Open the earnings call
EPS
$18.43
Expected
$13.76
Surprise
+33.9%
Stock, day of the call
+13.3%
View Earnings Call

Regeneron Pharmaceuticals insiders are selling within their usual range

Insider trading · Last trade on Nov 4, 2026

Sold $20.1m 11 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Past 12 months

Continue 0R2M Research

Decided on Regeneron Pharmaceuticals? Get an email when 0R2M reaches the price you’d buy at. Free with an account.

Other Regeneron Pharmaceuticals listings

What is the Intrinsic Value of one 0R2M stock?

The intrinsic value for Regeneron Pharmaceuticals Inc (0R2M) under the Base Case is USD.

Is 0R2M stock undervalued or overvalued?

Compared with the current market price of 924.8081 USD, the stock appears .

How reliable are our estimates? See how past valuations played out
Back to Top